Testicular Germ-Cell Tumours · Medical Oncology · First salvage · randomized phase III

TIGER: TIP versus TI-CE

For relapsed or refractory GCT after first-line cisplatin, does conventional-dose TIP or high-dose TI-CE provide better outcomes as first salvage treatment?

Randomized comparison; outcome results not yet posted in sources reviewed

Population

Planned 420

Study population as reported in the cited publication; cohort sizes and denominators are stated where available.

Evidence type

Randomized phase III · mixed GCT

Not all evidence is randomized, comparative, or seminoma-specific.

Reported outcomes

TIGER (Alliance A031102; NCT02375204) is a phase III trial comparing four cycles of conventional-dose TIP with TI-CE, which uses paclitaxel/ifosfamide for mobilization followed by high-dose carboplatin/etoposide and autologous stem-cell rescue.

Results pending. No efficacy bar is drawn because outcome results are not posted in the registry source reviewed. The graphic below represents trial status, not an outcome estimate.

Trial status

Ongoing

Bars visualize source-reported percentages; where the denominator is shown, it is the observed count/denominator rather than a comparative treatment effect. NNT is not calculated for single-arm cohorts or non-randomized comparisons.

Interpretation and limitations

As of the registry update reviewed 16 October 2026, the study was active but not recruiting, with completion projected for 2031 and no results posted. Do not infer efficacy or superiority before results are reported.

Guideline context: ESMO–EURACAN recommends standard-dose VIP/PEI, TIP or VeIP as conventional first salvage options after relapse following cisplatin-based chemotherapy. NCCN Testicular Cancer Guidelines Insights (Version 2.2025) is a contemporary US guideline source. The study summarized here is not necessarily seminoma-specific; histology scope is stated explicitly below.

Guidelines: ESMO–EURACAN 2022 · NCCN Insights v2.2025

Primary study source

Alliance A031102 / TIGER, NCT02375204.

Original study / PubMed / registry ↗

Evidence review date: 18 October 2026. Confirm regimen choice and dose schedules against current guideline text and an expert germ-cell tumour multidisciplinary team.